TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Utility of Oxygen Insufflation During Flexible Fiberoptic Bronchoscope-guided Intubation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients who have surgery under general oral endotracheal anesthesia with invasive arterial blood pressure monitoring~Exclusion Criteria:~* history of lung disease~* abnormality in chest x-ray~* anticipating difficult intubation~* pregnant women~* who is unable to understand and agree the consent form

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Oxygen (Type: EXPERIMENTAL): Oxygen is supplied through suction port in bronchoscope during bronchoscope-guided intubation.
- Control (Type: NO_INTERVENTION): Bronchoscope-guided intubation is performed without oxygen supply.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VALERIA: Valsartan in Combination With Lisinopril in Hypertensive Patients With Microalbuminuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with mild to moderate hypertension with a mean sitting diastolic blood pressure (MSDBP) \> 85 and \< 110 mmHg for non-treated patients. Previously treated patients with MSDBP \< 110 mmHg. Treated is defined as having taken medication until \< 2 days prior to Visit 1~* Positive urine spot test with Micral dipstick (detection of urinary albumin concentration of at least 50 mg/l) at Visit 1 (day -21).~* Confirmation of MAU of at least 2 out of 3 measurements determined in the first morning urine samples performed at Visit 1 day-21), Visit 2 (day -14) or Visit 3 (day -7). MAU is defined for male patients as urinary albumin creatinine ratio (UACR) \> 2.5 mg/mmol and \< 25.0 mg/mmol and for female patients as UACR \> 3.5 mg/mmol and \< 35.0 mg/mmol at both visits.~Exclusion Criteria:~* Evidence of renal impairment as determined by any one of the following:~  * serum creatinine clearance \< 30 ml/min as determined by Cockroft and Gault formula \[Cockroft and Gault, 1976\] and/or~ * serum creatinine \> 1.25 x ULN at Visit 1,~ * a history of dialysis, or~ * a history of nephrotic syndrome.~* Serum potassium values \<3.5 mmol/l or \>5.5 mmol/l at Visit 1~* Any medical condition which might significantly alter the urinary excretion of albumin~Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Beta-Blocker Therapy and Phosphodiesterase Inhibition on Cardiac Neurohormonal Activation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* scheduled for major vascular surgery~* can sign informed consent before surgery~* documented CAD or risk factors for CAD~Exclusion Criteria:~* Preoperative treatment with beta-adrenergic agonists or glucocorticoids,~* electrocardiographic (ECG) abnormalities like nonsinus rhythm, second- or third degree heart block, or left bundle branch block,~* cardiac pacemaker dependency,~* symptomatic mitral or aortic valvular disease,~* a history of asthma, bronchospasm, or severe chronic obstructive pulmonary disease necessitating bronchodilator therapy,~* severe liver dysfunction~* known allergies against the study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of BRAF V600 mutant High Grade glioma that had relapsed, progressed or failed to respond to frontline therapy~* Diagnosis of BRAF V600 mutant Low Grade glioma with progressive disease following surgical excision, or non-surgical candidates with necessity to begin first systemic treatment because of a risk of neurological impairment with progression.~* Confirmed measurable disease~Key Exclusion Criteria:~* Previous treatment with dabrafenib, trametinib, other RAF inhibitor, other MEK or ERK inhibitor~* HGG patient: Cancer treatment within the past 3 weeks. LGG patient: Any systemic therapy or radiotherapy prior to enrollment~* LGG patients: history of allergic reaction or contraindications to the use of carboplatin or vincristine~* Stem cell transplant within the past 3 months~* History of heart disease~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- LGG cohort: dabrafenib and trametinib (Type: EXPERIMENTAL): Participants in the LGG cohort randomized to receive dabrafenib (orally, twice daily and dosed based on weight and age) in combination with trametinib (orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on weight)
- LGG cohort: carboplatin and vincristine (Type: ACTIVE_COMPARATOR): Participants in the LGG cohort randomized to receive active comparator chemotherapy (carboplatin and vincristine). Participants received one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy.
- HGG cohort: dabrafenib and trametinib (Type: EXPERIMENTAL): Participants in the HGG cohort received dabrafenib (orally, twice daily and dosed based on weight and age) and trametinib (orally, once daily in combination with the first daily dose of dabrafenib and dosed based on weight)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Clamp Ancillary Study for Assessment of Insulin Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Meets eligibility criteria of the main study, Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (NCT01881828).~Exclusion Criteria:~1. Low hemoglobin or hematocrit as defined by each local institution's rules for insulin clamps or if no institutional requirements a Hematocrit \<30% or hemoglobin \<10 gm/dL

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Oral Placebo (Type: PLACEBO_COMPARATOR): A central pharmacy will compound a placebo to match the metformin tablets.~The placebo product will contain the following components:~* Micosolle™, silica based excipient~* Silicified Micro Crystalline Cellulose, National Formulary~* Safflower Oil, United States Pharmacopeia~* K-30 Povidone Powder~* Magnesium Stearate, National Formulary (Vegetable source)~* Fumed Silica, National Formulary
- Metformin (Type: EXPERIMENTAL): Metformin 2000 mg per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pain Medications Following Thyroidectomy and Parathyroidectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or greater~* Undergoing total thyroidectomy, partial thyroidectomy or parathyroidectomy at MetroHealth Medical Center~Exclusion Criteria:~* Patients taking narcotics prior to surgery~* Patients who are unable or unwilling to follow study protocol requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Narcotic group regimen (Type: OTHER): * Tylenol tablet 1000 mg by mouth every 8 hours alternating with~* Ibuprofen tablet 800 mg by mouth every 8 hours~* Oxycodone 5 mg by mouth every 6 hours as needed for pain, #10 tablet or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg.
- Non-narcotic group regimen (Type: ACTIVE_COMPARATOR): * Tylenol tablet 1000 mg by mouth every 8 hours alternating with~* Ibuprofen tablet 800 mg by mouth every 8 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Lansoprazole in Chronic Post Nasal Drip

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Negative RAST inhalant allergy panel OR negative skin testing (Group A)~* Positive RAST or Positive skin testing AND insufficient response to all of the following: (Group B)~  * Allergen avoidance~ * Topical nasal steroids~ * Allergy shots if indicated~ * Antihistamines~ * Negative CT sinuses (coronal)~ * \< 4mm of mucosal thickening and \< 3 sinus sites~ * Absence of air-fluid levels~ * Negative anterior rhinoscopy~ * Absence of pus, crusts on mucosal surfaces~Exclusion Criteria:~* Age \< 18~* Pregnancy, confirmed by urine pregnancy test at day of randomization~* Ciliary dyskinesia~* Immune deficiency~* Cystic fibrosis~* Diagnosis of acute sinusitis or chronic RS (AAO-HNS)~* Active use of topical decongestant~* Use of PPI within the last 30 days~* Previous fundoplication~* Uncontrolled thyroid disease~* Isolated chronic cough without the symptom of post nasal drip

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lansoprazole (Type: ACTIVE_COMPARATOR): None
- Sugar Pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Approach Bias Retraining to Augment Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients ages 18-65 capable of providing informed consent~* Willing and able to provide informed consent, attend all study visits, and comply with the protocol~* Daily smoker for at least 1 year~* Currently smoke an average of at least 5 cigarettes per day~* Report a motivation to quit smoking of at least 5 on a 10-point scale~Exclusion Criteria:~* A lifetime history of bipolar disorder, schizophrenia, psychosis, or delusional disorders; an eating disorder in the past 6 months; organic brain syndrome, mental retardation or other cognitive dysfunction that could interfere with capacity to engage in therapy; a history of substance or alcohol abuse or dependence (other than nicotine) in the last 6 months or otherwise unable to commit to refraining from alcohol use during the acute period of study participation.~* Visual or hand-motoric impairments~* Current use of nicotine replacement therapy~* Current use of any other pharmacotherapy or psychotherapy for smoking cessation not provided by the researchers during the quit attempt~* Current use of tobacco products other than cigarettes~* Insufficient command of the English language as the treatment manual is written only in English and study staff are not fluent in other languages

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Approach Bias Retraining Group (Type: EXPERIMENTAL): Individuals in this condition will receive seven sessions of ABR training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the training may weaken automatic cigarette-approach and strengthen automatic cigarette-avoidance. Furthermore, they will be told that the opposite effect will be true for the stimuli not related to cigarettes (i.e., the positive stimuli).
- Control Group (Type: SHAM_COMPARATOR): Individuals in this condition will receive seven sessions of SHAM training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the purpose of the training is to improve control over these automatic tendencies and that following the training sessions, they will easily be able to push or pull the stimuli regardless of content.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy, postmenopausal women who seek treatment for hot flashes~* Patients using hormone replacement therapy(HRT) must be willing to discontinue treatment~* Patients must be experiencing moderate to severe hot flashes~* Patients must be able to sign the informed consent~* Patients must be able to enter simple commands and complete questionnaires on the frequency and severity of their hot flashes using an electronic diary~Other inclusions apply.~Exclusion Criteria:~* Patients with hypersensitivity to Gabapentin~* Patients with severe chronic diarrhea, chronic constipation, uncontrolled irritable bowel syndrome (IBS) or unexplained weight loss~* Patients treated with estrogen pellets or injectable progestin drug therapy within 6 months.~* Patients currently treated with Gabapentin or Pregabalin for any indication, including vasomotor symptoms~Other exclusions apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Gabapentin Extended Release (Type: EXPERIMENTAL): Active treatment
- Placebo (Type: OTHER): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a primary diagnosis of ADHD~* Females of childbearing potential must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test~* Male or non-pregnant female subject who agrees to comply with any applicable contraceptive requirements~Exclusion Criteria:~* Subject has a current, uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as severe comorbid Axis II disorders or severe Axis I disorders~* Subject weighs less than 55 lbs or is morbidly overweight with a BMI =\> 35~* Subject has a history of seizure during the last 2 years or a serious tic disorder, including Tourette's Disorder~* Subject is pregnant or lactating

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- SPD503 (Guanfacine HCl) (1 mg) (Type: EXPERIMENTAL): None
- SPD503 (2 mg) (Type: EXPERIMENTAL): None
- SPD503 (3 mg) (Type: EXPERIMENTAL): None
- SPD503 (4 mg) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Early Hypertension Among Persons Living With HIV in Haiti

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PLWH 18-65 years of age~* ART duration ≥ 1 year, stable regimen ≥ 6 months~* HIV 1-RNA \< 1,000 copies/mL within past 12 months~* Pre-HTN (SBP 120-139 or DBP 80-89 mm Hg)~* No current antihypertensive treatment~* Receives HIV care at GHESKIO~* Willing to provide consent~Exclusion Criteria:~* Pregnancy~* Kidney disease or diabetes~* On protease inhibitor/ritonavir~* Advanced illness with limited life expectancy~* Plans to move out of the area within the next year~* Clinician determination that patient is unstable on ART

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Early hypertension) (Type: EXPERIMENTAL): Participants randomized to the early HTN treatment arm will initiate 5mg daily of amlodipine immediately, increasing to 10 mg if SBP \>130 mmHg after 1 month.
- Standard of Care (Type: NO_INTERVENTION): Participants randomized to the SOC arm will not be initiated on any medications initially. They may be initiated on amlodipine only if they develop HTN (SBP ≥140 or DBP ≥90 mm Hg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Male~* History of erectile dysfunction (ED) for at least 3 months duration~* Anticipate having the same female partner willing to participate throughout the study~* At least 18 years of age at Visit 1 and agree to make at least 4 sexual attempts during the early phase of the study~* Adequate partner sexual function as determined by a Female Sexual Function Index~* Willing to record responses to efficacy questionnaires, sexual quality of life questionnaires and other instruments used in the study~Exclusion Criteria:~* May not participate in the study if you have taken tadalafil previously.~* History of cardiac conditions including angina requiring treatment with nitrates, heart disease of coronary conditions including myocardial infarction, bypass surgery, angioplasty or stent placement for specified time before starting the study.~* Have sexual partner not willing to complete the scales.~* Use of nitrates.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: ACTIVE_COMPARATOR): 5 mg tadalafil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-Small Cell Lung Cancer disease~* Clinical stage IV or recurrent disease~* One prior first-line platinum-based chemotherapy regimen with or without maintenance therapy~* For Non-Small Cell Lung Cancer (NSCLC) tumors other than squamous cell histology, the epidermal growth factor receptor (EGFR) mutation status is known prior to randomization~* For participants with activating epidermal growth factor receptor (EGFR) mutation only, prior epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) monotherapy (only one regimen in the setting of single use) should be utilized~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1~* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version RECIST version 1.1~* Adequate organ function~* Estimated life expectancy of at least 3 months.~Exclusion Criteria:~* Have undergone major surgery within 28 days prior to randomization or have planned major surgery during study treatment~* Receiving concurrent treatment with other anticancer therapy~* Central nervous system disease other than stable and treated brain metastasis~* Has major blood vessel invasion or encasement by cancer~* Has intratumor cavitation~* Has a history of uncontrolled thrombotic disorder~* Is receiving therapeutic anticoagulation with drugs~* Is receiving chronic therapy with nonsteroidal anti-inflammatory drugs~* Has a history of hemoptysis within 2 months prior to randomization~* Has clinically relevant congestive heart failure~* Has experienced any arterial thromboembolic event~* Has uncontrolled arterial hypertension~* Has had a serious or nonhealing wound or, ulcer~* Has significant existing conditions

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ramucirumab plus Docetaxel (Type: EXPERIMENTAL): Ramucirumab 10 milligram per kilogram (mg/kg) on Day 1 of every 21 day cycle, administered as an intravenous (IV) infusion over approximately 60 minutes. Docetaxel 60 milligram per square meter (mg/m2) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
- Placebo plus Docetaxel (Type: PLACEBO_COMPARATOR): Placebo (administered at a volume equivalent to a dose of milligram per kilogram (mg/kg)) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes. Docetaxel 60 mg/m2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete